Douglas Bootle
Impact in
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
-
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 5
- Cancer therapeutics and mechanisms 2
- Polyamine Metabolism and Applications 2
- Oncology 3
- Cancer Treatment and Pharmacology 1
- Co-authors
- Peter Charlton (3 shared papers)Wendy Dangerfield (3 shared papers)Prakash Mistry (3 shared papers)Alistair J. Stewart (3 shared papers)Cornelia Quadt (6 shared papers)Dejan Juric (5 shared papers)Jordi A. Rodon (4 shared papers)Howard A. Burris (4 shared papers)
- Journals
- Clinical Cancer Research (2 papers)Anti-Cancer Drugs (2 papers)Lung Cancer (1 paper)Journal of Clinical Oncology (1 paper)British Journal of Clinical Pharmacology (1 paper)
- Partner nations
- SwitzerlandUnited StatesNetherlands
In The Last Decade
Douglas Bootle
13 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 69
- Oncology 353
- Cancer Research 102
- Molecular Biology 471
- Pulmonary and Respiratory Medicine 163
- Otorhinolaryngology 27
Countries citing papers authored by Douglas Bootle
This map shows the geographic impact of Douglas Bootle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Bootle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Bootle more than expected).
Fields of papers citing papers by Douglas Bootle
This network shows the impact of papers produced by Douglas Bootle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Bootle. The network helps show where Douglas Bootle may publish in the future.
Co-authors
The 25 scholars most cited alongside Douglas Bootle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 358 | |
| 2 | In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. | 2001 | 315 |
| 3 | 2018 | 216 | |
| 4 | 2009 | 80 | |
| 5 | 2002 | 57 | |
| 6 | 2004 | 50 | |
| 7 | 2001 | 47 | |
| 8 | BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study | 2012 | 37 |
| 9 | 2014 | 29 | |
| 10 | 2004 | 17 | |
| 11 | 2023 | 12 | |
| 12 | 2014 | 11 | |
| 13 | 2024 | 6 |
About Douglas Bootle
Douglas Bootle is a scholar working on Molecular Biology, Oncology, Modeling and Simulation, Otorhinolaryngology and Pulmonary and Respiratory Medicine, having authored 13 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer therapeutics and mechanisms (2 papers), Polyamine Metabolism and Applications (2 papers), Lung Cancer Treatments and Mutations (1 paper), Lymphoma Diagnosis and Treatment (1 paper), Advanced Breast Cancer Therapies (1 paper), Cancer Treatment and Pharmacology (1 paper) and Head and Neck Cancer Studies (1 paper). The work is most often cited by research in Oncology (353 citations), Cancer Research (102 citations), Molecular Biology (471 citations), Pulmonary and Respiratory Medicine (163 citations) and Otorhinolaryngology (27 citations). Douglas Bootle has collaborated with scholars based in Switzerland, United States and Netherlands. Frequent co-authors include Peter Charlton, Wendy Dangerfield, Prakash Mistry, Alistair J. Stewart, Cornelia Quadt, Dejan Juric, Jordi A. Rodon, Howard A. Burris, Jane A. Plumb and Christopher Liddle. Their work appears in journals such as Clinical Cancer Research, Anti-Cancer Drugs, Lung Cancer, Journal of Clinical Oncology and British Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.